Adagene (ADAG) fell 13% pre-market after pricing a $70 million American depository share offering at a 19% discount. The company also provided a positive update from a Keytruda combination trial for colorectal cancer. Retail sentiment on Stocktwits remained bearish following the pricing news. The offering is set to close on April 6, 2026.